Vladimir Coric

Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019.

Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA.

Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT.

VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice.